Angiogenesis is critical for tumor growth and metastasis. VEGF is an important mediator of angiogenesis and has emerged as a leading target for cancer therapy. Bevacizumab, a monoclonal antibody to VEGF, has demonstrated improved overall survival when given in combination with carboplatin and paclitaxel in advanced nonsquamous non-small-cell lung cancer. VEGF receptor tyrosine kinase inhibitors are active as monotherapy in advanced non-smallcell lung cancer but have not improved survival when given in combination with chemotherapy. Identification of predictive biomarkers for antiangiogenic agents is a major focus of ongoing investigations. Agents targeting important mediators of angiogenesis are currently being evaluated.
All Science Journal Classification (ASJC) codes